More than 500 Million worldwide suffer type-2 diabetes.
We offers a variety of biomarkers on our diabetes test panel. Besides running a normal A1C test, we goes further and tests a patient’s Fasting Glucose, GlycoMark, Adiponectin, Leptin, HOMA-IR, Insulin, and C-peptide, but we don’t stop there. To give patient’s a look at the bigger picture, we also run a Comorbidity Assessment of Cardiovascular and Renal biomarkers, as well as a Genetic Predisposition test called DIABETESpredict™. With DIABETESpredict™, doctors can help their patients know their risk for type 2 diabetes earlier.
Clear Health Pass MdDiabeticPro is also specifically designed to help Type 1 diabetes patients with the management of the disease. This test can be used for monitoring individuals who are pre-disposed to insulin resistance. The results of the test equip physicians with the information needed to fine tune nutrition and exercise plans, helping a T1D patient to make the use of insulin most effective.
DIABETESpredict™ is a genotyping tool for type 2 diabetes risk assessment. It analyzes the main genetic variants associated with T2D, taking into account multi-ethnic associations. DIABETESpredict™ identifies high risk individuals and gives them additional information to implement lifestyle changes. Early identification of type 2 diabetes enables prevention and with DIABETESpredict™ doctors are empowered to help their patients further.
Clear Health Pass Holdings, LLC (“Clear Health Pass”) operates as a Specification Developer, developing specifications for devices distributed under its name, and is listed with the Food and Drug Administration. However, the Company does not engage in manufacturing activities.
Clear Health Pass Holdings, LLC (“Clear Health Pass”) operates as a Specification Developer, developing specifications for devices distributed under its name, and is listed with the Food and Drug Administration. However, the Company does not engage in manufacturing activities.
As a Specification Developer, the Company may also arrange for the manufacturing of devices labeled with another establishment’s
name by a contract manufacturer.
The distribution of collection kits, specimen transport, marketing, test distribution, and actual testing is performed by a high-complexity Clinical Laboratory Improvement Amendments (CLIA) lab.
All testing conducted by the CLIA lab is compliant with the Centers for Medicare and Medicaid Services (CMS) CLIA Lab Amendments Act.
Clear Health Pass™ LLC acts as Authorized Representative of tribal, federally chartered corporations formed under Section 17 of the Indian Reorganization Act (IRA), U.S.C. Title 25.
(800) 266-7207
(212) 313-9529
© 2023 Clear Health Pass Holdings™, LLC., All trademark references are trademarks of either the Clear Health Pass Holdings, LLC or their respective owners.